Background Knowledge of the real-world effectiveness and safety of tofacitinib for ulcerative
colitis (UC) is relevant to confirm the benefit observed in clinical trials. Methods This …

Summary Background The LIR! C trial showed that laparoscopic ileocaecal resection is a
cost-effective treatment that has similar quality-of-life outcomes to treatment with infliximab …

Summary The coronavirus disease 2019 (COVID-19) pandemic is changing the
management of many chronic diseases, including that of patients with inflammatory bowel …

Therapeutic advances in the management of IBD have led to a paradigm shift in the
assessment of IBD disease activity. Beyond clinical remission, objective assessment of …

Fecal calprotectin (FC) has emerged as one of the most useful tools for clinical management
of inflammatory bowel diseases (IBD). Many different methods of assessment have been …

It is unclear whether ulcerative colitis (UC) is a progressive disease similar to Crohn's
disease (CD). Patients with UC often are undertreated because of the possibility of curative …

This article reports on the sixth scientific workshop of the European Crohn's and Colitis
Organisation [ECCO] on the pathogenesis of extraintestinal manifestations [EIMs] in …

Background & Aims Histopathology is an emerging treatment target in ulcerative colitis (UC)
clinical trials. Our aim was to provide guidance on standardizing biopsy collection protocols …

Introduction Etrolizumab is a next-generation anti-integrin with dual action that targets two
pathways of inflammation in the gut. A robust phase 3 clinical program in ulcerative colitis …

Ulcerative colitis (UC) is a chronic disease that can present at various stages of disease
activity and severity. Depending on disease activity at any moment and the overall severity …